Fulgent Genetics Statistics
Share Statistics
Fulgent Genetics has 30.59M shares outstanding. The number of shares has increased by 2.24% in one year.
| Shares Outstanding | 30.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.92M |
| Failed to Deliver (FTD) Shares | 7 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 645.62K, so 2.11% of the outstanding shares have been sold short.
| Short Interest | 645.62K |
| Short % of Shares Out | 2.11% |
| Short % of Float | 3.23% |
| Short Ratio (days to cover) | 4.54 |
Valuation Ratios
The PE ratio is -5.13 and the forward PE ratio is -37.57.
| PE Ratio | -5.13 |
| Forward PE | -37.57 |
| PS Ratio | 2.98 |
| Forward PS | 1.9 |
| PB Ratio | 0.76 |
| P/FCF Ratio | 179.54 |
| PEG Ratio | n/a |
Enterprise Valuation
Fulgent Genetics Inc. has an Enterprise Value (EV) of 778.49M.
| EV / Earnings | -4.64 |
| EV / Sales | 2.69 |
| EV / EBITDA | -16.72 |
| EV / EBIT | -10.71 |
| EV / FCF | 162.32 |
Financial Position
The company has a current ratio of 6.96, with a Debt / Equity ratio of 0.
| Current Ratio | 6.96 |
| Quick Ratio | 6.96 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.36 |
| Cash Flow / Debt | 6.51 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.15% and return on capital (ROIC) is -6.37%.
| Return on Equity (ROE) | -0.15% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -6.37% |
| Revenue Per Employee | 244.27K |
| Profits Per Employee | -141.74K |
| Employee Count | 1.18K |
| Asset Turnover | 0.23 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.15M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -30.66% in the last 52 weeks. The beta is 1.51, so Fulgent Genetics 's price volatility has been higher than the market average.
| Beta | 1.51 |
| 52-Week Price Change | -30.66% |
| 50-Day Moving Average | 19.64 |
| 200-Day Moving Average | 21.21 |
| Relative Strength Index (RSI) | 55.81 |
| Average Volume (20 Days) | 208.22K |
Income Statement
In the last 12 months, Fulgent Genetics had revenue of $289.21M and earned -$167.82M in profits. Earnings per share was $-5.63.
| Revenue | 289.21M |
| Gross Profit | 104.46M |
| Operating Income | -72.69M |
| Net Income | -167.82M |
| EBITDA | -46.55M |
| EBIT | -72.69M |
| Earnings Per Share (EPS) | -5.63 |
Balance Sheet
The company has $97.47M in cash and $15.25M in debt, giving a net cash position of $82.22M.
| Cash & Cash Equivalents | 97.47M |
| Total Debt | 15.25M |
| Net Cash | 82.22M |
| Retained Earnings | 633.17M |
| Total Assets | 1.23B |
| Working Capital | 252.55M |
Cash Flow
In the last 12 months, operating cash flow was $27.00M and capital expenditures -$22.21M, giving a free cash flow of $4.80M.
| Operating Cash Flow | 27.00M |
| Capital Expenditures | -22.21M |
| Free Cash Flow | 4.80M |
| FCF Per Share | 0.16 |
Margins
Gross margin is 36.12%, with operating and profit margins of -25.14% and -58.03%.
| Gross Margin | 36.12% |
| Operating Margin | -25.14% |
| Pretax Margin | -60.19% |
| Profit Margin | -58.03% |
| EBITDA Margin | -16.1% |
| EBIT Margin | -25.14% |
| FCF Margin | 1.66% |
Dividends & Yields
FLGT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -28.81% |
| FCF Yield | 0.8% |
Analyst Forecast
The average price target for FLGT is $22, which is 12.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $22 |
| Price Target Difference | 12.6% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 4.66 |
| Piotroski F-Score | 3 |